At a ribbon-cutting ceremony in New Haven February 29, Alexion dedicated its new global headquarters in New Haven to rare disease patients worldwide.
The manufacturer of drugs used to treat rare diseases was founded in New Haven in 1992, relocated to Cheshire eight years later and now has returned to the city. Stanley Choy, co-chairman of CURE, predicted Alexion’s move will draw other companies to the New Haven area, continuing to build the industry in the state.
Spokeswoman Stephanie Fagan said 2015 was a “pivotal year” as Alexion added two rare-disease drugs to its previous one-drug portfolio. Soliris, which treats very rare blood disorders, was Alexion’s first commercial product.
It has since developed Strensiq, which treats a metabolic disease leading to defective bone mineralization and skeletal abnormalities, and Kanuma, for patients with a buildup of fats in tissue cells that can lead to liver and cardiovascular disease.